生長抑素類似物市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球生長抑素類似物市場價值為 72 億美元，預計到 2034 年將以 7.2% 的複合年成長率成長，達到 143 億美元。由於肢端肥大症、神經內分泌腫瘤和庫欣氏症等荷爾蒙相關疾病的盛行率不斷上升，市場持續獲得成長動力。隨著世界各地的醫療保健系統更加重視早期發現和個人化治療，生長抑素類似物 (SSA) 正成為首選的治療方案。它們調節過量荷爾蒙分泌的能力，加上藥物配方和輸送技術的不斷創新，使它們非常適合慢性疾病的管理。

隨著患者和醫療保健提供者對荷爾蒙失調的認知不斷提高，對有效、微創和長效療法的需求也在激增。此外，醫學界向綜合護理途徑的轉變正在鼓勵更廣泛地採用 SSA，並得到多個地區優惠的報銷框架和監管批准的支持。藥物傳遞的進步（例如長效注射劑）尤其透過提供更大的便利性和提高患者的依從性來推動藥物的採用。市場也受益於針對更廣泛治療應用的臨床研究的激增，從而為新的治療領域打開了大門。

光是蘭瑞肽一項，2024 年的收入就達到 39 億美元。其快速成長反映了被診斷患有神經內分泌腫瘤的患者數量的增加。蘭瑞肽的受歡迎程度源於其長效配方，這顯著降低了給藥頻率——這對患者和醫生來說都是一個有吸引力的因素。它能夠透過更少的注射提供一致的治療效果，從而提高治療依從性。監管機構繼續透過批准新的適應症來支持其擴大用途，這進一步加強了其臨床相關性。隨著越來越多的研究探索其在治療其他荷爾蒙相關疾病方面的功效，蘭瑞肽在不同的護理環境中繼續獲得應用。

以適應症分類，神經內分泌腫瘤在 2024 年佔據最大的市場佔有率，為 46.8%。這種主導地位很大程度上得益於改進的診斷工具和成像技術，這些技術有助於早期和準確地檢測。患者意識的提高和醫生對針對性治療的偏好導致 SSA 處方量顯著增加。隨著腫瘤學實踐日益轉向精準醫療，生長抑素類似物正成為長期腫瘤管理不可或缺的一部分。它們能夠有效控制症狀，並且具有良好的安全性，這增強了人們的採用率。

2024 年，美國生長抑素類似物市場產值達 30 億美元。該國先進的醫療保健基礎設施、廣泛的診斷影像服務以及強大的保險覆蓋範圍都為這一強勁的市場地位做出了貢獻。透過公共和私人保險管道獲得經批准的 SSA 療法可確保患者更好地獲得治療。罕見內分泌疾病的篩檢計畫正變得越來越普遍，有助於早期診斷和及時治療。

主要參與者包括 Teva Pharmaceuticals、GlyTech、Ipsen Pharma、Sun Pharmaceutical、輝瑞、諾華、Debiopharm、Chiasma、Camurus、Crinetics Pharmaceuticals、Peptron 和 Dauntless Pharmaceuticals，他們正在大力投資長效注射劑和智慧輸送系統，旨在提高依從性和療效。這些公司優先考慮監管參與以簡化核准流程，同時也專注於透過臨床研究和研發合作擴大治療適應症。戰略許可、併購活動和全球擴張努力在加強其在生長抑素類似物領域的立足點方面發揮核心作用。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 荷爾蒙相關疾病盛行率不斷上升
    • 生長抑素類似物藥物和製劑的進展
    • 提高認知和診斷
    • 生長抑素類似物的應用不斷擴大
  • 產業陷阱與挑戰
    • 發展中地區的認知有限
    • 來自替代療法的競爭
• 成長潛力分析
• 監管格局
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按類型，2021 - 2034 年

• 主要趨勢
• 奧曲肽
• 蘭瑞肽
• 帕瑞胜肽

第6章：市場估計與預測：按適應症，2021 - 2034 年

• 主要趨勢
• 神經內分泌腫瘤（NET）
• 肢端肥大症
• 其他適應症

第7章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 口服
• 腸外

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 醫院
• 專科診所
• 其他最終用途

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Camurus
• Chiasma
• Crinetics Pharmaceuticals
• Dauntless Pharmaceuticals
• Debiopharm
• GlyTech
• Ipsen Pharma
• Novartis
• Peptron
• Pfizer
• Sun Pharmaceutical
• Teva Pharmaceuticals

The Global Somatostatin Analogs Market was valued at USD 7.2 billion in 2024 and is estimated to grow at a CAGR of 7.2% to reach USD 14.3 billion by 2034. The market continues to gain momentum due to the rising prevalence of hormone-related conditions such as acromegaly, neuroendocrine tumors, and Cushing's disease. With healthcare systems worldwide placing greater emphasis on early detection and personalized treatments, somatostatin analogs (SSAs) are emerging as a preferred therapeutic solution. Their ability to regulate excess hormone secretion, coupled with ongoing innovations in drug formulation and delivery technologies, makes them highly suitable for chronic disease management.

As awareness about hormonal disorders increases among patients and healthcare providers, the demand for effective, minimally invasive, and long-acting therapies is surging. Moreover, the medical community's shift toward integrated care pathways is encouraging the wider adoption of SSAs, supported by favorable reimbursement frameworks and regulatory approvals across multiple regions. Advancements in drug delivery-such as long-acting injectables-are especially driving uptake by offering greater convenience and boosting patient compliance. The market is also benefiting from a surge in clinical research targeting broader therapeutic applications, thus opening doors to novel treatment areas.

The Lanreotide segment alone generated USD 3.9 billion in 2024. Its rapid growth reflects the increasing number of patients being diagnosed with neuroendocrine tumors. Lanreotide's popularity stems from its long-acting formulation, which significantly reduces the frequency of administration-an appealing factor for both patients and physicians. Its ability to deliver consistent therapeutic effects with fewer injections enhances treatment adherence. Regulatory authorities continue to support its expanded use by approving new indications, which further strengthens its clinical relevance. As more studies explore its efficacy in treating additional hormone-related conditions, lanreotide continues to gain ground across diverse care settings.

By indication, neuroendocrine tumors accounted for the largest market share at 46.8% in 2024. This dominance is largely driven by improved diagnostic tools and imaging technologies that facilitate early and accurate detection. The rise in patient awareness and physician preference for targeted treatments has led to a notable uptick in SSA prescriptions. With oncology practices increasingly turning to precision medicine, somatostatin analogs are becoming integral to long-term tumor management. Their ability to offer effective symptom control with a favorable safety profile is reinforcing their adoption.

The U.S. Somatostatin Analogs Market generated USD 3 billion in 2024. The country's advanced healthcare infrastructure, widespread access to diagnostic imaging, and strong insurance coverage have all contributed to this robust market presence. The availability of approved SSA therapies through both public and private insurance channels ensures better patient access. Screening programs for rare endocrine diseases are becoming more prevalent, aiding in early diagnosis and timely treatment.

Key players, including Teva Pharmaceuticals, GlyTech, Ipsen Pharma, Sun Pharmaceutical, Pfizer, Novartis, Debiopharm, Chiasma, Camurus, Crinetics Pharmaceuticals, Peptron, and Dauntless Pharmaceuticals, are heavily investing in long-acting injectables and smart delivery systems aimed at improving adherence and outcomes. These companies are prioritizing regulatory engagement to streamline approval processes while also focusing on expanding therapeutic indications through clinical research and R&D collaborations. Strategic licensing, M&A activities, and global expansion efforts are playing a central role in strengthening their foothold in the somatostatin analogs space.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hormone-related disorders
    • 3.2.1.2 Advancements in somatostatin analog drugs and formulations
    • 3.2.1.3 Increasing awareness and diagnosis
    • 3.2.1.4 Expanding application of somatostatin analogs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited awareness in developing regions
    • 3.2.2.2 Competition from alternative therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter’s analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Octreotide
• 5.3 Lanreotide
• 5.4 Pasireotide

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Neuroendocrine tumor (NET)
• 6.3 Acromegaly
• 6.4 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Camurus
• 10.2 Chiasma
• 10.3 Crinetics Pharmaceuticals
• 10.4 Dauntless Pharmaceuticals
• 10.5 Debiopharm
• 10.6 GlyTech
• 10.7 Ipsen Pharma
• 10.8 Novartis
• 10.9 Peptron
• 10.10 Pfizer
• 10.11 Sun Pharmaceutical
• 10.12 Teva Pharmaceuticals